Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Metall Zug AG ( (CH:METN) ) has provided an update.
Metall Zug reported a sharp decline in 2025 results as the deconsolidation of Belimed and a weaker U.S. dollar weighed on revenues and earnings, pushing net sales down to CHF 194.6 million and EBIT to CHF –17.5 million, despite only marginal organic sales slippage. The medical devices arm Haag-Streit suffered from price pressure, currency headwinds and one-off restructuring and product phase-out costs, although its newly launched digital slit lamp and phoropter, together with the Metis surgical microscope, were well received and form the core of a strategy to refresh and digitalize the portfolio while normalizing R&D spending.
In parallel, the Technologycluster & Infra unit accelerated the build-out of Tech Cluster Zug, lifting investments to CHF 40.4 million and securing a CHF 220 million syndicated loan to fund the next development phase, which includes SHL Medical’s new headquarters and production facility and a planned ETH Learning Factory presence. While EBIT in this unit slipped to break-even due to higher depreciation and downstream costs, the secured financing, incoming industrial tenants and prospective academic anchor are set to strengthen Metall Zug’s asset base and position Tech Cluster Zug as a high-profile innovation hub, even as a leadership change installs Silvan Burkhalter as the unit’s CEO from April 2026.
The most recent analyst rating on (CH:METN) stock is a Hold with a CHF737.00 price target. To see the full list of analyst forecasts on Metall Zug AG stock, see the CH:METN Stock Forecast page.
More about Metall Zug AG
Metall Zug AG is a Swiss industrial group with activities spanning medical devices and real estate development, notably through its Haag-Streit ophthalmic equipment subsidiary and the Tech Cluster Zug industrial site. The company focuses on high-end diagnostic and surgical technologies for eye care and on transforming its Zug site into a mixed industrial, research and infrastructure ecosystem anchored by tenants such as V-ZUG and upcoming partner SHL Medical.
YTD Price Performance: -12.99%
Average Trading Volume: 151
Technical Sentiment Signal: Sell
Current Market Cap: CHF318.3M
For a thorough assessment of METN stock, go to TipRanks’ Stock Analysis page.